Five Women File Joint Lawsuit Over BioZorb Breast Implant Side Effects

Hologic failed to update the BioZorb breast implant’s warning label despite receiving Medical Device Reports of pain, migration, infections and other complications, lawsuit alleges.

A multi-plaintiff BioZorb lawsuit claims Hologic Inc. compounded the struggles of breast cancer survivors by marketing a defective implant that can cause infections, break through the skin, and fail to dissolve as intended, often requiring surgical removal.

Sharon Durrell, Brittany Crothers, Antoinnette Davis, Julie Rios and Mary Quigley filed the joint complaint (PDF) in the U.S. District Court for the District of Massachusetts on September 5, joining about 200 other women with similar BioZorb lawsuits, each indicating that Hologic’s tissue marker implant was defective and unreasonably dangerous.

The BioZorb implant was designed for use in breast cancer survivors and others who require targeted radiation therapy. It consists of a biodegradable spacer made of polylactic acid and six titanium clips. The spacer is supposed to dissolve safely and be absorbed into the body, leaving behind the titanium clips as an indicator to other physicians that those areas had already been treated.

However, in recent years the U.S. Food and Drug Administration (FDA) began to receive reports of the BioZorb breast implant side effects, including migrating out of position, protruding through the skin, or causing other complications when it failed to absorb into the body as intended, leading to a BioZorb recall in October 2024.

Each of the claims report similar experiences as those reported to the FDA, indicating that the manufacturer prioritized profits over patients’ safety, and failed to warn breast cancer patients or their doctors about the true risk of BioZorb complications.

The multi-plaintiff lawsuit alleges Hologic was long aware of BioZorb breast implant side effects, having access to Medical Device Reports (MDRs) from women who went through painful complications shortly after the device hit the market, but failed to update label warnings.

“Hologic, upon information and belief, received product inquiries, complaints, and reports of injuries caused by BioZorb, including, but not limited to, infection, fluid buildup, device migration, device erosion, pain, discomfort, rash, extended resorption time of the device, and additional surgeries.”

— Sharon Durrell et al v. Hologic Inc.

All five women share similar stories, that they experienced pain and discomfort after BioZorb implantation, with their doctors having to surgically remove the tissue marker after realizing it had failed to absorb properly. All five at first feared the hard lump made by the BioZorb was a return of their cancer.

They present claims of design defect, failure to warn, manufacturing defect, negligence, and breach of implied warranty of merchantability. They seek both compensatory and punitive damages.

September 2025 BioZorb Lawsuits Update

Given common questions of fact and law raised in the complaints, the BioZorb lawsuit will be centralized with other cases in the District of Massachusetts, where Hologic is headquartered, before U.S. District Judge Allison D. Burroughs, who is presiding over coordinated discovery and pretrial proceedings.

To help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the claims, Judge Burroughs previously directed the parties to prepare a group of four BioZorb lawsuits for early bellwether trials. The first BioZorb lawsuit trial is scheduled to go before a jury on January 20, 2026.

While the outcome of the bellwether trials will not have any impact on other claims being pursued against the manufacturer, the average BioZorb lawsuit payouts awarded by juries are likely to have a substantial impact on negotiations needed to avoid each claim ultimately being set for trial in the future.

To stay up to date on this litigation, sign up to receive BioZorb lawsuit updates sent directly to your inbox.